Shares of Delcath (NSDQ:DCTH) dropped again yesterday on news of the FDA’s final decision regarding its Melblez Kit liver cancer treatment.
Delcath Systems Inc.
Delcath to pare 20% of its U.S. workforce | Personnel Moves
Queensbury, N.Y.-based Delcath (NSDQ:DCTH) announced last week that it plans to pare its workforce by about 20%, the latest in a series of layoff announcements from the oncology devices maker. This is the 3rd time this year that Delcath has announced imminent layoffs, having announced smaller cuts in April and larger layoffs in January.
Edwards Lifesciences CFO Abate to retire | Personnel Moves
Edwards Lifesciences (NYSE:EW) said its finance chief, Thomas Abate, plans to retire later this year after a replacement is found.
The Irvine, Calif.-based medical device company said Abate, 60, will stay on as CFO while the search goes on. Edwards hired Peter Crist of Crist/Kolder Associates to assist in the quest, according to a press release.
Delcath plunges after FDA panel recommends against liver cancer treatment approval
German reimbursement win sends Delcath shares up 8%
Delcath’s cancer-treating system lands U.S., Australian regulatory wins
Medical device company Delcath Systems (NSDQ:DCTH) is on a roll, notching a couple new regulatory milestones this month for its organ-isolating ChemoSat chemotherapy treatment systems.
Cancer: Delcath lands expanded CE Mark for organ-isolating chemo treatment
Delcath Systems (NSDQ:DCTH) won expanded CE Mark approval in the European Union for its ChemoSat organ-isolating cancer treatment system, landing indication for a new drug used to target liver tumors.
FDA accepts Delcath’s application for drug-device chemotherapy combo
The FDA agreed to review Delcath Systems’ (NSDQ:DCTH) new drug application, bringing the device maker 1 step closer to launching its organ-isolating chemotherapy system on the U.S. market.
Delcath files new FDA application for chemo drug-device combination
Delcath Systems (NSDQ:DCTH) filed a new FDA application for the latest iteration of its ChemoSat drug-device combination, the Generation 2 device, in treatment of patients with non-operable liver cancer.